Graybug Vision (NASDAQ:GRAY – Get Rating) had its price target trimmed by Cantor Fitzgerald from $4.00 to $2.50 in a report released on Wednesday, The Fly reports. Cantor Fitzgerald also issued estimates for Graybug Vision’s FY2022 earnings at ($1.97) EPS.
A number of other analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Graybug Vision from a sell rating to a hold rating in a research report on Wednesday, April 27th. Wedbush reissued a neutral rating and set a $3.00 target price on shares of Graybug Vision in a research report on Thursday, March 31st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Graybug Vision presently has an average rating of Hold and an average price target of $3.56.
Graybug Vision stock opened at $0.83 on Wednesday. The business has a 50 day moving average of $1.14 and a 200-day moving average of $1.70. Graybug Vision has a 1 year low of $0.72 and a 1 year high of $7.06.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in shares of Graybug Vision by 221.3% in the 1st quarter. Renaissance Technologies LLC now owns 35,341 shares of the company’s stock worth $43,000 after purchasing an additional 24,341 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Graybug Vision by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 455,572 shares of the company’s stock worth $561,000 after purchasing an additional 23,846 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Graybug Vision in the 1st quarter worth $125,000. Advisor Group Holdings Inc. bought a new position in shares of Graybug Vision in the 1st quarter worth $740,000. Finally, State Street Corp lifted its holdings in shares of Graybug Vision by 70.7% in the 4th quarter. State Street Corp now owns 35,073 shares of the company’s stock worth $64,000 after purchasing an additional 14,525 shares in the last quarter. Institutional investors own 52.88% of the company’s stock.
About Graybug Vision (Get Rating)
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
- Get a free copy of the StockNews.com research report on Graybug Vision (GRAY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.